title: Is inhibition of cancer angiogenesis and growth by paclitaxel schedule dependent?
authors.affiliation: University of California, Davis Cancer Center and Veteran Administration Northern California Health System, Sacramento, CA, USA. derick.lau@ucdmc.ucdavis.edu
authors.forename: Derick
authors.initials: D
authors.lastname: Lau
authors.forename: Linlang
authors.initials: L
authors.lastname: Guo
authors.forename: David
authors.initials: D
authors.lastname: Gandara
authors.forename: Lawrence J T
authors.initials: LJ
authors.lastname: Young
authors.forename: Ling
authors.initials: L
authors.lastname: Xue
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000818:Animals; D045744:Cell Line, Tumor; D004334:Drug Administration Schedule; D005260:Female; D006131:Growth Inhibitors / Q000008:administration & dosage*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D008819:Mice, Nude; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000473:pathology*; D017239:Paclitaxel / Q000008:administration & dosage*; D023041:Xenograft Model Antitumor Assays / Q000379:methods
chemical_list: D020533:Angiogenesis Inhibitors; D006131:Growth Inhibitors; D017239:Paclitaxel